Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fusion protein of human somatostatin tetradecapeptide and human serum albumin, and coding gene and preparation method thereof

A human serum albumin and fusion protein technology, applied in the field of long-acting fusion protein drugs, can solve the problem that the physiological function is inferior to natural SST, etc., and achieve the effects of changing the pharmacokinetic characteristics, reducing the mortality rate and prolonging the retention time.

Inactive Publication Date: 2012-03-28
JIANGSU INST OF NUCLEAR MEDICINE
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although people have designed a series of SST analogues with better body tolerance, such as octreotide, vapreotide, lanreotide, etc., to prolong the plasma half-life to 120 minutes, but these analogues only interact with some receptors With high affinity, it is far inferior to natural SST in terms of physiological functions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein of human somatostatin tetradecapeptide and human serum albumin, and coding gene and preparation method thereof
  • Fusion protein of human somatostatin tetradecapeptide and human serum albumin, and coding gene and preparation method thereof
  • Fusion protein of human somatostatin tetradecapeptide and human serum albumin, and coding gene and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0063] 1. Cloning of the SST-14 triplet gene

[0064] a. (SST-14) 3 Oligonucleotide annealing

[0065] Artificially synthesized two complementary (SST-14) 3 Oligonucleotides (see (SS-14) 3 - oligonucleotide sequence 1 and (SS-14) 3 - oligonucleotide sequence 2). 10l to 70l ddH for each of oligonucleotide sequences 1 and 2 at a concentration of 100M 2 O, simultaneously add 10l 10 annealing buffer to prepare 10M (SS14) 3 - Oligonucleotide mixed solution. After heating the oligonucleotide mixed solution at 95C for 2 minutes, let the oligonucleotide mixed solution cool down to room temperature (25C-30C).

[0066] b. (SST-14) 3 extend

[0067] 30 l annealed oligonucleotide template, 10 l10 Klenow buffer, 10 l 25 mM dNTPs, mixed, incubated at 37C for 30 minutes. Add 4 l of 100 mM EDTA to stop the reaction.

[0068] c. (SST-14) 3 PCR amplification

[0069] The reaction system is: 0.5l of 10μmol / L PS1 and PS2 primers, 0.5l of 10mmol / L dNTP, 2.5μl of 10pfu buffer, 0.5...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Average weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a fusion protein of human somatostatin tetradecapeptide and human serum albumin, comprising a first region homologous with at least 85% sequence of the human somatostatin tetradecapeptide and a second region homologous with at least 85% sequence of the human serum albumin or a second region with partial amino acid sequence of the human serum albumin, wherein the first region homologous with the human somatostatin tetradecapeptide is positioned at the N terminal of the fusion protein, the second region homologous with the human serum albumin is positioned at the C terminal of the fusion protein, and no connecting peptide is added between the first and second regions; or the second region homologous with at least 85% sequence of the human serum albumin is positioned at the N terminal of the fusion protein, the first region homologous with at least 85% sequence of the human somatostatin tetradecapeptide is positioned at the C terminal of the fusion protein, and no connecting peptide is added between the first and second regions. The fusion protein disclosed by the invention prolongs the retention time of the human somatostatin tetradecapeptide molecules in the blood circulation system, and can be used for treating various diseases caused by surplus secretion of growth hormone, for treating diseases caused by endocrine disorder of gastrointestinal tract, for inhibiting growth of tumors expressing somatostatin receptors (SSTRs) and not expressing SSTRs, and for reducing the death rate caused by radiation injury of gastrointestinal tract.

Description

technical field [0001] The invention belongs to the technical field of long-acting fusion protein drugs, and in particular relates to a fusion protein of human somatostatin tetradecapeptide and human serum albumin. Background technique [0002] Somatostatin (somatostatin, SST) is a cyclic polypeptide hormone. It is a somatotropin release-inhibiting factor (SRIF) isolated and purified from sheep hypothalamus by Brazeau et al. in 1973. It mainly contains 14 peptides (SST-14) and 28 peptides (SST28) in two natural forms. SST exerts a variety of biological activities by binding to specific receptors (Somatostatin receptors, SSTRs) on the target cell membrane. There are five molecular subtypes of SSTRs, SSTR1-5, and SSTR2 has two variants, SSTR2A and SSTR2B, which all bind to natural SST-14 and SST28 with similar affinity. In addition to inhibiting growth hormone, SST can inhibit almost all physiological endocrine reactions of the body, and can extensively inhibit cell prolifer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00C12N15/62C12N15/63C12N5/10C12N1/15C12N1/19C12N1/21C12N15/81
Inventor 付强杨润林丁月娣李文新范俊
Owner JIANGSU INST OF NUCLEAR MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com